CareDx Brings Home-Based Monitoring to Transplant Patients

In the age of COVID-19 and social-distancing, diagnostic companies have to provide more than just assays. CareDx has tapped into this idea and launched a solution that will enable remote home-based monitoring of transplant patients. The South San Francisco, CA-based company said its RemoTraC can help reduce visits to busy labs and hospitals and that immunosuppressed transplant patients at the highest risk during the COVID-19 pandemic can limit their potential exposure. Typically, transplant patients require frequent blood tests which normally require in-person visits to draw sites at labs or hospitals. “Because of our digital solutions, we’re able to monitor these patients on a very regular interval because many times the surveillance isn’t happening at the transplant center with the frequency that is needed,” Peter Maag, Chairman and CEO of CareDx, told MD+DI. “We have a care team that makes sure these patients are continuously being followed up.” He added, “the new feature is that we can do this with mobile phlebotomy. On the one hand, it’s non-invasive technology, on the other hand, its technology of caring for those patients longitudinally after implantation.” RemoTraC will be offered to all patients who want their transplant monitoring lab tests to be drawn from the comfort of their home by trained mobile phlebo...
Source: MDDI - Category: Medical Devices Authors: Tags: COVID-19 Implants Source Type: news